You can buy or sell Catabasis and other stocks, options, ETFs, and crypto commission-free!
Catabasis Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is edasalonexent, which is intended for the treatment of Duchenne muscular dystrophy. Read More The company was founded by Michael R. Jirousek, Jill C. Milne, and Steven E. Shoelson on June 26, 2008 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Yahoo FinanceMay 15
SV Life Sciences Advisers, LLC Buys Catabasis Pharmaceuticals Inc, Sells KalVista ...
- By insider Boston, MA, based Investment company SV Life Sciences Advisers, LLC buys Catabasis Pharmaceuticals Inc, sells KalVista Pharmaceuticals Inc, Avrobio Inc during the 3-months ended 2019Q1, according to the most recent filings of the investment company, SV Life Sciences Advisers, LLC. As of 2019Q1, SV Life Sciences Advisers, LLC owns 7 stocks with a total value of $150 million. These are the details of the buys and sells. New Purchases: CATB, CATB, Reduced Positions: KALV, AVRO, DCPH, F...
Seeking AlphaMay 14
Catabasis Pharma net loss improves in Q1
Catabasis Pharmaceuticals (CATB) Q1 results: Revenues: $0; R&D Expense: $4.2M (-19.2%); SG&A: $2.1M (-12.5%); Net Loss: ($6M) (+22.1%); Loss Per Share: ($0.62) (+78.5%); Quick Assets: $51.7M (+37.5%); CF Ops (3M): ($6.6M) (+2.9%). Top-line results from the Phase 3 PolarisDMD trial expected in H2 2020, commercial registration of edasalonexent expected in early 2021. Shares are up 5% premarket. Previously: Catabasis Pharmaceuticals beats by $0.07 (May 14)...
Yahoo FinanceMay 2
Catabasis Pharmaceuticals to Present Data from the MoveDMD® trial of Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 71st Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, today announced that it will present data on edasalonexent treatment in boys affected by Duchenne muscular dystrophy (DMD) from the MoveDMD trial open-label extension at the American Academy of Neurology 71st Annual Meeting to be held May 4 to May 10, 2019 in Philadelphia, PA. Richard Finkel, M.D., Chief, Division of Neurology, Department of Pediatrics at Nemours Children’s Health System...
-$0.69 per share
-$0.62 per share